Receptor tyrosine-protein kinase erbB-2 is a protein that normally resides in the membranes of cells and is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene originally isolated from the avian genome.

2025年3月30日 · ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2) is a Protein Coding gene. Diseases associated with ERBB2 include Visceral Neuropathy, Familial, 2, Autosomal Recessive and Glioma Susceptibility 1. Among its related pathways are Drug-mediated inhibition of ERBB2 signaling and Signaling by ERBB2 KD Mutants.

In humans, the family includes Her1 (EGFR, ErbB1), Her2 (ErbB2), Her3 (ErbB3), and Her4 (ErbB4). The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are homologous: erythroblastic leukemia viral oncogene.

ERBB2 amplification is an established therapeutic target in breast and gastric cancers, but efforts to translate this finding to other solid tumors with ERBB2 amplification have not been effective. Recently the focus has turned to targeting activating ERBB2 mutations.

ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, also known as HER2 and neu) is a gene that encodes for the receptor tyrosine-protein kinase erbB-2. ERBB2 has been found to be amplified with an increased copy number in several cancers (PMID: 20185938).

ErbB2 promotes breast cancer metastatic potential via HSF1/LDHA axis-mediated glycolysis. ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma.

The erbB2 (also known as HER2 or neu) gene encodes a 185-kDa transmembrane glycoprotein, which belongs to the epidermal growth factor receptor (EGFR) family. ErbB2 is a receptor tyrosine kinase with intrinsic tyrosine kinase activity.

The EGF receptor (ERBB1) and related family member HER2/neu (ERBB2) are often overexpressed in aggressive breast cancers and their overexpression is correlated with poor prognosis. Clinical studies using ERBB inhibitors have focused on tumor growth ...

2020年5月4日 · ErbB2 amplification or overexpression is observed in ~25–30% of breast cancers and is associated with an aggressive clinical phenotype.

4 天之前 · ERBB2/ERBB3 Amplification Pan-Tumor Landscape The distribution of amplification ratios for tumors with a) ERBB2 and b) ERBB3 amplification in tissue biopsies as assessed by FoundationOne®CDx is shown. Amplification ratio is equal to the ratio of the modeled gene copy number to sample ploidy. Tumor types representing the highest proportion of ...